LUMOSA THERAPEUTICS CO., LTD.
🇹🇼Taiwan
- Country
- 🇹🇼Taiwan
- Ownership
- Public
- Established
- 2001-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.lumosa.com.tw
Clinical Trials
8
Active:0
Completed:4
Trial Phases
2 Phases
Phase 1:4
Phase 2:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
Phase 1
4 (50.0%)Phase 2
4 (50.0%)A Study to Evaluate the Safety and Efficacy of Multiple Doses of LT3001 Drug Product in AIS Subjects
Phase 2
Completed
- Conditions
- Acute Ischemic Stroke
- Interventions
- Drug: LT3001 Drug ProductDrug: Placebo
- First Posted Date
- 2022-06-03
- Last Posted Date
- 2025-06-08
- Lead Sponsor
- Lumosa Therapeutics Co., Ltd.
- Target Recruit Count
- 89
- Registration Number
- NCT05403866
- Locations
- 🇺🇸
Chattanooga Center for Neurologic Research, Chattanooga, Tennessee, United States
A Study to Evaluate the Safety and Efficacy of LT3001 Drug Product in Subjects AIS Undergoing EVT
Phase 2
Recruiting
- Conditions
- Acute Ischemic Stroke
- Interventions
- Drug: LT3001 Drug ProductDrug: Placebo
- First Posted Date
- 2022-01-20
- Last Posted Date
- 2025-06-05
- Lead Sponsor
- Lumosa Therapeutics Co., Ltd.
- Target Recruit Count
- 66
- Registration Number
- NCT05198323
- Locations
- 🇺🇸
CHI Memorial Hospital, Chattanooga, Tennessee, United States
🇨🇳Taichung Medical University, Taichung, Taiwan
A Study to Evaluate Safety and PK of Multiple Doses of LT3001 Drug Product and Drug-drug Interaction in Healthy Subjects
Phase 1
- Conditions
- Acute Ischemic Stroke
- Interventions
- First Posted Date
- 2021-03-22
- Last Posted Date
- 2021-03-22
- Lead Sponsor
- Lumosa Therapeutics Co., Ltd.
- Target Recruit Count
- 64
- Registration Number
- NCT04809818
- Locations
- 🇺🇸
Lumosa Phase 1 Unit, Cypress, California, United States
Study to Investigate the Safety of LT5001 Drug Product for Uremic Pruritus in Hemodialysis Patients
- First Posted Date
- 2020-05-19
- Last Posted Date
- 2020-05-28
- Lead Sponsor
- Lumosa Therapeutics Co., Ltd.
- Target Recruit Count
- 78
- Registration Number
- NCT04393675
- Locations
- 🇨🇳
China Medical University Hospital, Taichung, Taiwan
A Bioavailability Study of NALDEBAIN ER Injection and Nalbuphine Injection in Healthy Volunteers.
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2021-11-19
- Lead Sponsor
- Lumosa Therapeutics Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT04256434
- Locations
- 🇺🇸
WCCT Global Inc., Cypress, California, United States
- Prev
- 1
- 2
- Next
News
No news found